Thermo Fisher Scientific Inc
Most Recent
Materials Sector Stocks Weigh Market Down, Might Be Time to Buy
What Lies Ahead for Thermo Fisher’s Life Sciences Solutions Business?
TMO’s Life Sciences Solutions segment registered revenue growth of around 11% in 1Q16. The company reported strong growth in biosciences.
Analyst Recommendations for Thermo Fisher Scientific
Based on recommendations by 21 broker firms surveyed by Bloomberg, the consensus rating for Thermo Fisher Scientific was “buy” from 19 of the firms and “hold” from two of the firms.
How BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17
Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.
Analyzing the MFS Growth Fund’s 2015 Portfolio
The information technology, consumer discretionary, and healthcare sectors form the core of the MFS Growth Fund.
Microsoft Infiltrates the Mobile App Space: The Xamarin Acquisition
On February 24, Microsoft announced that it will acquire Xamarin, a mobile app platform provider. Financial details of the deal were not disclosed.
What Analysts Recommend for Accelerate Diagnostics and Peers
Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.
Varian Medical Systems’ Oncology Devices Are Key to Sales Growth
Varian Medical Systems commands the majority share of the oncology device market in the United States.
What Analysts Predict for Thermo Fisher’s 2Q17 Revenues
Wall Street estimates that Thermo Fisher Scientific’s (TMO) 2Q17 revenue will come in at ~$4.9 billion, a rise of ~8.5% on a YoY (year-over-year) basis.
What’s Expected of Baxter International in Fiscal 2017?
Baxter International (BAX) has updated its sales guidance growth from 2.0%–3.0% to approximately 4.0% on a constant currency basis.
Paulson & Co. eliminates position in Freeport-McMoRan
Freeport-McMoRan is the world’s largest publicly traded copper producer. It posted revenue of $5.7 billion, down 7.6%, saying, results “reflect lower oil volumes and price realizations for copper, gold and oil.”
Paulson & Co. ups position in Covidien
The Ireland-based Covidien is engaged in the development, manufacture, and sale of healthcare products for use in clinical and home settings. Its fourth-quarter net sales increased 7% to $2.73 billion.
Boston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35.
Thermo Fisher Scientific: What’s Been Driving Growth?
In this series, we discuss the major drivers of Thermo Fisher Scientific’s valuation, stock performance. and growth fundamentals.
What Are Leon Cooperman’s Top Holdings?
In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Zimmer Biomet Stock Regains Momentum: What’s Driving Growth?
Ximmer Biomet (ZBH) has risen 2.1% since its 1Q17 earnings release on April 27, 2017. The results exceeded analysts’ estimates, but ZBH lowered its 2017 guidance.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
TMO’s Oncomine Target Test Launch Will Boost This Business
On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.
How Are Stryker’s Core Strategies Working Toward Its Growth?
Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.
BD’s Stock Price Performance after Recent 52-Week High
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.
Analyst Recommendations for TMO Stock after 1Q18 Earnings Release
As of April 25 and according to a recent Reuters survey of 16 research firms, TMO stock is rated a “strong buy” by eight analysts.
Key positions traded by Paulson & Co. in 3Q14
Paulson & Co. was founded in 1994 by John Paulson. Unconfirmed sources say the firm posted a 14% loss in its event-driven Paulson Advantage fund in October.
Can Boston Scientific Surpass Its Earnings Estimates in 3Q17?
BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
BD Lifesciences’s Performance and Core Focus Areas
BDX’s Lifesciences business generated revenues of ~$3.8 billion in fiscal 2016, ended September 30, 2016.
Can BAX Stock Maintain Momentum after Recent Highs?
BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
Thermo Fisher’s Next Big Deal in the Medical Device Industry
On May 15, 2017, Thermo Fisher (TMO) announced the acquisition of Patheon (PTHN) for ~$7.2 billion, which includes ~$2 billion of net debt assumption.
Paulson & Co. opens a new position in PetSmart
PetSmart announced a broad cost-reduction strategy that will target all areas of the business. The company said it expects to realize savings before the end of fiscal 2015.
Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
On April 25, Thermo Fisher Scientific (TMO) announced its results for 1Q18. Its revenues rose 23% YoY to $5.9 billion.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
How Has Thermo Fisher Scientific’s Stock Performed Recently?
Thermo Fisher Scientific (TMO) was trading at $140.3 on November 28, 2016.
Why is leverage a double-edged sword for companies like Apple?
Corporate bond issuance in the U.S. reached $1.4 trillion in 2013, according to the Securities Industry and Financial Markets Association (SIFMA), a new record.
How Will Abbott Laboratories Benefit from Its Alere Acquisition?
On April 14, 2017, Abbott Laboratories (ABT) agreed to acquire point-of-care diagnostics player Alere (ALR) for an equity value of ~$5.3 billion.
What to Expect from Medtronic’s Diabetes Segment
In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.
How Wall Street Views Stryker After its 3Q17 Results
Analysts’ recommendations on Stryker Stryker (SYK) announced its 3Q17 earnings results on October 26, 2017. In this article, we’ll look at analysts’ ratings, recommendations, and target prices for Stryker over the next 12 months. As of October 30, 2017, of 28 investment research companies surveyed by Reuters, 17 (61%) recommended “buy” for Stryker, nine recommended “hold,” and two recommended […]
Assessing Abbott’s 3Q17 Expectations by Segment
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
What Analysts Recommend for BDX before Its 3Q17 Results
Becton Dickinson (BDX) plans to release its fiscal 3Q17 results on August 3. In a survey of 15 firms, ~66.7% of the analysts rated BDX as a “buy,” and 33.3% rated it as a “hold.”
What’s Thermo Fisher Scientific’s Latest Valuation?
After the release of its 2Q16 earnings results on July 28, 2016, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) multiple of 17.9x–18.5x.
Illumina Stock Continues Its Bull Run
Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.
In 4Q 2013, which positions does Third Point bet on?
Third Point revealed new positions and sell outs during the fourth quarter in its 13F filing this month.
How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Taking Stock of Thermo Fisher as the Year Wraps Up
In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.
Analysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Understanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
How Johnson & Johnson’s Medical Device Business Stands Now
Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.
Thermo Fisher’s Third-Quarter Revenue Estimates
The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.
What to Expect from Thermo Fisher’s Third-Quarter Earnings
Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
What ResMed’s Valuation Trend Indicates
The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.
What’s the Upside Potential for Agilent Technologies Stock?
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.
What Waters Corporation’s Valuation Trend Indicates
In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
Taking Stock of Quest Diagnostics’ Recent Acquisitions
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues.
How Quest Diagnostics Is Positioned in 2018
Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.
What’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.
What’s Driving the Growth in Thermo Fisher Scientific’s Segments?
Thermo Fisher Scientific (TMO) operates in four business segments.
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).
Thermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
How Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.
A Performance Overview of Roche’s Diagnostics Division
In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.
What Analysts Recommend for Haemonetics
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.
Thermo Fisher’s Q2 2018 Estimates: Revenue Growth Expected
Wall Street analysts expect Thermo Fisher’s (TMO) revenues to reflect 18.1% growth to $5.9 billion during the second quarter.
Can HOLX Stock Rebound from Its Recent Lows?
On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.
Discussing BDX’s Recent Stock Price Performance
On March 28, 2018, Becton, Dickinson and Company (BDX) ended trading at a closing price of $212.43.
What Are Thermo Fisher Scientific’s Current Valuations?
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x.
How TMO Stock Has Performed Recently
On March 14, 2018, Thermo Fisher Scientific (TMO) closed at $213.46 per share.
What Investors Should Know about TMO’s Dividends
On March 14, 2018, Thermo Fisher Scientific (TMO) stock started trading ex-dividend.
A Look at Thermo Fisher Scientific’s Recent Research Partnerships
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, and consumables, diagnostics and research software, and services.
A Look at TMO’s New High Pressure Ion Chromatography System
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of its new high-pressure Ion Chromatography System.
TMO’s Advanced Laboratory Management System Could Gain Market Share
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.
A Look at Stryker’s Recent Dividend Announcement
On February 7, 2018, Stryker (SYK) announced a quarterly dividend of $0.47 per share.
Abbott Laboratories: ABT Stock’s Wall Street Recommendations
Abbott Laboratories (ABT) has recorded strong growth recently, registering stellar performance.
Boston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates
Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
How Bard Acquisition Could Benefit BD
Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.
What BD Expects for 2018
BD posted 1Q18 results as a standalone company and didn’t include Bard sales in 1Q18.
How BD Stock Has Performed in the Last Year
On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.
Why Abbott Laboratories Plans to Focus on Organic Growth in 2018
Abbott’s plan will be to focus on organic growth over the next year and going forward, after a slew of major acquisitions and strategic divestitures.
Thermo Fisher Scientific Stock Hit 52-Week High on January 23
On January 23, 2018, Thermo Fisher Scientific (TMO) traded at its 52-week high of $217.22. However, it closed at $214.55.
Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
What Are Accelerate Diagnostics’ Key Strengths?
In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.
Does Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
What’s the Competitive Landscape for Accelerate Diagnostics?
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
Stryker Stock: Wall Street Recommendations and Target Price
Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17.
Baxter International Expected to Post Strong 4Q17 Results
Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]
Wall Street Shows Confidence in BAX Stock
Analysts’ recommendations Baxter International (BAX), one of the United States’ leading medical technology companies, offers renal and hospital solutions to healthcare providers. The company has witnessed strong growth momentum recently, and Wall Street has grown increasingly bullish on the company’s growth prospects. In this article, we’ll look at analysts’ recent recommendations, ratings, and price targets for BAX stock. […]
A Look at Thermo Fisher Scientific’s Recent Stock Price Performance
TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.
Why Leerink Swann Lowered Its 2018 Estimates for TMO Stock
On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.
Wall Street Analysts’ ‘Buy’ Ratings and Recommendations on TMO Stock
On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.
TMO’s Acquisition from EPTEK Technology Could Boost Its China Opportunity
On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.
TMO’s Oncomine Dx Target Test Gets CMS Coverage
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
Thermo Fisher Scientific’s Deepening Ties with Sema4
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
TMO’s Launch of New Research Assay for Cancer
On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.
